BioSpace News Archive

Nektar Therapeutics reported financial results for the first quarter ended March 31, 2024.

Natera, Inc., a global leader in cell-free DNA and genetic testing, reported its financial results for the first quarter ended March 31, 2024.

CytoSorbents Corporation (NASDAQ: CTSO), a pioneer in critical care and cardiac surgery blood purification technologies, today reported unaudited financial and operating results for the quarter ended March 31, 2024.

Arcellx, Inc. and Kite, a Gilead Company, announced several key operational updates on their partnered anitocabtagene autoleucel multiple myeloma program.

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a review of recent clinical and business highlights.

CareDx, Inc. – reported financial results for the first quarter ended March 31, 2024.

Kite, a Gilead Company, and Arcellx, Inc. announced several key operational updates on their partnered anitocabtagene autoleucel multiple myeloma program.

Revance Therapeutics, Inc. (NASDAQ: RVNC), today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update.

Travere Therapeutics, Inc., announced that the Company will present nine abstracts in rare kidney disease at the National Kidney Foundation Spring Clinical Meetings in Long Beach, California, May 14-18, 2024, and the European Renal Association Congress in Stockholm, May 23-26, 2024.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted 17 new employees options to purchase a total of 141,100 shares of the Company’s common stock at an exercise price per share of $15.26, which was the closing price on May 8, 2024, and restricted stock units to acquire a total of 70,555 shares of the Company’s common stock.